Sima Qutaina

A peptide vaccine targeting ANG2 reduces AVM number and size and normalizes vascular diameters in HHT mice without causing organ dysfunction.

This study develops bispecific antibodies that activate the ALK1-BMPRII pathway, reducing AVMs and improving symptoms in HHT mouse models.

This study identifies CDK6-driven cell cycle acceleration in endothelial cells as a driver of arteriovenous malformations in HHT, suggesting CDK4/6 inhibitors as potential therapeutic options.